Fixed-Dose Combination Fenofibrate/Pravastatin 160/40 mg Versus Simvastatin 20 mg Monotherapy in Adults With Type 2 Diabetes and Mixed Hyperlipidemia Uncontrolled With Simvastatin 20 mg: A Double-Blind, Randomized Comparative Study

Clinical Therapeutics

Volumn 33, Issue 1, 2011, Pages 1-12

  Farnier, Michel ^a   Steinmetz, Armin ^b   Retterstøl, Kjetil ^c   Császár, Albert ^d  

^a Point Medical   (France)

^b UNIVERSITY OF BONN   (Germany)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d State Health Center   (Hungary)

Author keywords

Combination therapy; Fenofibrate; Mixed hyperlipidemia; Pravastatin; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATININE; FENOFIBRATE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EYE SWELLING; FEMALE; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; STOMACH PAIN; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; URINE RETENTION;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FENOFIBRATE; FOLLOW-UP STUDIES; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PRAVASTATIN; SIMVASTATIN;

EID: 79952514709     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.02.006     Document Type: Article

References (29)

1. Rydén L., Standl E., Bartnik M., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007, 28:88-136. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC), European Association for the Study of Diabetes (EASD).
2. Executive summary: Standards of medical care in diabetes-2010. Diabetes Care 2010, 33(Suppl 1):S4-S10.
3. Fruchart J.C., Sacks F., Hermans M.P., et al. The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008, 102(Suppl 10):1K-34K.
4. Ginsberg H.N., Elam M.B., Lovato L.C., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574. ACCORD Study Group, [published correction appears in N Engl J Med. 2010;362:1748].
5. Jun M., Foote C., Lv J., et al. Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis. Lancet 2010, 375:1875-1884.
6. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239. National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, American Heart Association, [published correction appears in Circulation. 2004;110:763].
7. Farnier M. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: A critical review of potential benefits and drawbacks. Am J Cardiovasc Drugs 2003, 3:169-178.
8. Grundy S.M., Vega G.L., Yuan Z., et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005, 95:462-468. [published correction appears in Am J Cardiol. 2006;98:427-428].
9. Durrington P.N., Tuomilehto J., Hamann A., et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract 2004, 64:137-151.
10. Derosa G., Maffioli P., Salvadeo S.A., et al. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr Med Res Opin 2009, 25:1973-1983.
11. Fredrickson D.S., Levy R.I., Lees R.S. Fat transport in lipoproteins-An integrated approach to mechanisms and disorders. N Engl J Med 1967, 276:34-42. 94-103, 148-156, 215-225, 273-281.
12. Rifai N., King M.E. Immunoturbidimetric assays of apolipoproteins A, AI, AII, and B in serum. Clin Chem 1986, 32:957-961.
13. Walker G.A. Analysis of covariance. Common Statistical Methods for Clinical Research 2002, SAS Institute Inc, Cary, NC. 2nd ed. G.A. Walker (Ed.).
14. Betteridge D.J. Diabetic dyslipidaemias. Acta Diabetol 1999, 36:S25-S29.
15. Taskinen M.R. Diabetic dyslipidaemia: From basic research to clinical practice. Diabetologia 2003, 46:733-749.
16. Miller M., Cannon C.P., Murphy S.A., et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008, 51:724-730. PROVE IT-TIMI 22 Investigators.
17. Faergeman O., Holme I., Fayyad R., et al. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol 2009, 104:459-463. Steering Committees of IDEAL and TNT Trials.
18. Barter P., Gotto A.M., LaRosa J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301-1310. Treating to New Targets Investigators.
19. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. BMJ 2003, 326:1423.
20. Pan W.J., Gustavson L.E., Achari R., et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 2000, 40:316-323.
21. Gustavson L.E., Schweitzer S.M., Koehne-Voss S., et al. The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite. J Clin Pharmacol 2005, 45:947-953.
22. Farnier M., Ducobu J., Bryniarski L. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy. Am J Cardiol 2010, 106:787-792.
23. Corsini A., Bellosta S., Davidson M.H. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol 2005, 96(Suppl 9A):44K-49K. discussion 34K-35K.
24. Jacobson T.A. Myopathy with statin-fibrate combination therapy: Clinical considerations. Nat Rev Endocrinol 2009, 5:507-518.
25. Davidson M.H., Armani A., McKenney J.M., Jacobson T.A. Safety considerations with fibrate therapy. Am J Cardiol 2007, 99(Suppl 6A):3C-18C.
26. Farnier M. Update on the clinical utility of fenofibrate in mixed dyslipidemias: Mechanisms of action and rational prescribing. Vasc Health Risk Manag 2008, 4:991-1000.
27. Keating G.M., Croom K.F. Fenofibrate: A review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 2007, 67:121-153.
28. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9975 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005, 366:1849-1861. FIELD study investigators, [published corrections appears in Lancet. 2006;368:1415; Lancet. 2006;368:1420].
29. Chew E.Y., Ambrosius W.T., Davis M.D., et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010, 363:233-244. ACCORD Study Group, ACCORD Eye Study Group.